Wealth Alliance Advisory Group LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 9.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,274 shares of the company’s stock after acquiring an additional 981 shares during the quarter. Wealth Alliance Advisory Group LLC’s holdings in Johnson & Johnson were worth $1,368,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson in the first quarter valued at approximately $105,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $117,000. Princeton Capital Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $141,000. Smart Portfolios LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $150,000. Finally, Live Your Vision LLC lifted its stake in Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares during the period. 66.67% of the stock is currently owned by institutional investors.
In other news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by corporate insiders.
Several brokerages have issued reports on JNJ. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a research note on Friday, September 14th. Jefferies Financial Group set a $145.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Credit Suisse Group set a $151.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Finally, Sanford C. Bernstein began coverage on Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $143.91.
Shares of NYSE:JNJ opened at $133.87 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a market cap of $370.70 billion, a PE ratio of 18.34, a PEG ratio of 2.19 and a beta of 0.70.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The company had revenue of $20.83 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the firm earned $1.83 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.